Related Experiment Videos
Molecular prognostic factors in bladder cancer
J A Vet1, F M Debruyne, J A Schalken
1Department of Urology, University Hospital Nijmegen, The Netherlands.
World Journal of Urology
|January 1, 1994
Summary
Molecular markers show promise in predicting bladder cancer outcomes. DNA ploidy, epidermal growth factor receptor (EGFR), E-cadherin, and retinoblastoma (RB) expression offer prognostic insights, though further research is needed for definitive clinical relevance.
Area of Science:
- Oncology
- Molecular Pathology
Background:
- Bladder cancer prognosis relies on accurate staging and grading.
- Identifying reliable molecular prognostic markers is crucial for personalized treatment strategies.
Purpose of the Study:
- To evaluate the predictive value of various molecular prognostic parameters in bladder cancer.
- To determine the clinical relevance of these markers for different tumor stages and grades.
Main Methods:
- Analysis of DNA ploidy.
- Assessment of epidermal growth factor receptor (EGFR) expression.
- Evaluation of E-cadherin and retinoblastoma (RB) protein expression.
- Review of p53 and c-erbB-2 expression data.
Main Results:
- DNA ploidy is prognostic for grade 2 tumors; aneuploid tumors indicate a poor prognosis.
- EGFR overexpression predicts outcomes in superficial bladder tumors.
- Abnormal E-cadherin and RB expression are valuable for invasive tumors.
- Prognostic value of p53 and c-erbB-2 requires further investigation due to conflicting results.
Conclusions:
- Several molecular markers demonstrate potential prognostic value in bladder cancer.
- Further extensive studies are needed to establish the precise clinical relevance of these markers.
- Progression markers for superficial transitional cell carcinoma (TCC) warrant increased attention.